Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ITRM 
Iterum Therapeutics PLC (ITRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: ITRM (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 38.99% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 21.14M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 1 | Beta 2.88 | 52 Weeks Range 0.36 - 3.02 | Updated Date 12/4/2025 |
52 Weeks Range 0.36 - 3.02 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.72 |
Earnings Date
Report Date 2025-11-13 | When Before Market | Estimate -0.21 | Actual -0.2 |
Profitability
Profit Margin - | Operating Margin (TTM) -1982.31% |
Management Effectiveness
Return on Assets (TTM) -53.28% | Return on Equity (TTM) -555.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 44756019 | Price to Sales(TTM) 54.21 |
Enterprise Value 44756019 | Price to Sales(TTM) 54.21 | ||
Enterprise Value to Revenue 114.76 | Enterprise Value to EBITDA 0.55 | Shares Outstanding 48051157 | Shares Floating 52369601 |
Shares Outstanding 48051157 | Shares Floating 52369601 | ||
Percent Insiders 0.79 | Percent Institutions 5.3 |
Upturn AI SWOT
Iterum Therapeutics PLC
Company Overview
History and Background
Iterum Therapeutics PLC is a pharmaceutical company focused on developing and commercializing anti-infectives to treat multi-drug resistant pathogens. Founded in 2014, the company's primary focus has been on sulopenem, an antibiotic intended for oral and IV administration.
Core Business Areas
- Anti-Infectives Development: Iterum Therapeutics PLC focuses on the development and commercialization of novel anti-infectives to combat the growing problem of antibiotic resistance. Their primary focus is on sulopenem.
Leadership and Structure
The company's leadership team consists of experienced pharmaceutical executives. The organizational structure includes departments focused on research and development, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Sulopenem: Sulopenem is an investigational broad-spectrum penem antibiotic. It's intended for use in the treatment of infections caused by multi-drug resistant bacteria. As an investigational drug, there is no market share information. Competitors include companies developing and marketing other broad-spectrum antibiotics, such as Melinta Therapeutics (MLNTQ - delisted), Nabriva Therapeutics (NBRV), and Allergan (ABBV).
Market Dynamics
Industry Overview
The anti-infectives market is driven by the increasing prevalence of antibiotic-resistant bacteria and the growing need for new treatment options. The market is highly competitive, with numerous pharmaceutical companies developing and marketing antibiotics.
Positioning
Iterum Therapeutics PLC aims to address the unmet need for oral and IV antibiotics that can effectively treat infections caused by multi-drug resistant organisms. Their competitive advantage, if approved, lies in the convenience and potential cost-effectiveness of sulopenem compared to existing treatments.
Total Addressable Market (TAM)
The TAM for anti-infectives is estimated to be in the billions of dollars annually. Iterum, if it gets approval, is positioned to capture a portion of this TAM, specifically targeting infections caused by multi-drug resistant bacteria.
Upturn SWOT Analysis
Strengths
- Focus on unmet medical need
- Potential for oral and IV administration of sulopenem
- Experienced management team
Weaknesses
- Dependence on regulatory approval for sulopenem
- Limited financial resources
- Lack of commercialized products
- History of regulatory hurdles
Opportunities
- Growing prevalence of antibiotic resistance
- Potential for partnerships and collaborations
- Expansion into new indications
Threats
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Generic competition
- Changing reimbursement landscape
Competitors and Market Share
Key Competitors
- ABBV
- NBRV
Competitive Landscape
Iterum Therapeutics PLC faces intense competition from established pharmaceutical companies with greater financial resources and broader product portfolios. Its success depends on the differentiation and clinical efficacy of sulopenem.
Growth Trajectory and Initiatives
Historical Growth: Iterum Therapeutics PLC has not yet achieved significant revenue growth due to the lack of approved products. Growth is dependent on the successful development and commercialization of sulopenem.
Future Projections: Future growth is highly dependent on regulatory approval and commercial success of sulopenem. Analyst estimates vary significantly depending on the anticipated approval timeline and market adoption.
Recent Initiatives: Recent initiatives primarily focus on resubmitting sulopenem NDA's to regulatory bodies and securing additional funding.
Summary
Iterum Therapeutics PLC is a struggling pharmaceutical company with the core business of developing and commercializing anti-infectives. The company's success hinges on regulatory approval and commercialization of sulopenem. High competition with existing pharmaceutical companies is one thing the company needs to look out for. Because of the history of not getting the regulatory approval and the cash flow problems the company is currently facing, the company is weak.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Iterum Therapeutics PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-05-25 | President, CEO & Director Mr. Corey N. Fishman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://www.iterumtx.com |
Full time employees 9 | Website https://www.iterumtx.com | ||
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.